# Biologic Switching and Immunogenicity > Biologic switching for NEET-PG Pharmacology: anti-drug antibodies, loss of response, TDM decision grid, biosimilars and the CDSCO pathway. - Canonical URL: https://prepelephant.com/topics/neet-pg/pharmacology/biologic-switching-immunogenicity - Exam / course: NEET-PG · Subject: Pharmacology - Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team - First published: 2026-10-02 - Last updated: 2026-10-02 - How to cite: "Biologic Switching and Immunogenicity", PrepElephant, https://prepelephant.com/topics/neet-pg/pharmacology/biologic-switching-immunogenicity ## Direct answer Antibodies against a biologic can quietly end its career: immunogenicity — the formation of anti-drug antibodies (ADAs) — neutralises the molecule or accelerates its clearance, producing the infusion reactions and secondary loss of response that force a switch. Infliximab is the classic example; episodic dosing without an immunomodulator drives ADA formation in a substantial fraction of patients, which is why methotrexate or azathioprine co-therapy is standard, and why therapeutic drug monitoring (trough levels plus ADA titres) now guides the decision tree: low drug level with high antibodies means switch; low level without antibodies means dose intensification; high drug level with active disease means switch out of class. Biosimilar switching is governed by extrapolated indications and national regulatory positions rather than pharmacological doubt. ## What you must remember - **Immunogenicity consequences:** neutralising ADAs reduce trough concentrations (secondary loss of response) and cause acute or delayed infusion/injection reactions; binding ADAs mainly clear the drug faster. - **Risk factors:** episodic or interrupted dosing, mono-therapy without methotrexate or azathioprine, subcutaneous routes and high drug immunogenicity — infliximab and adalimumab head the list; etanercept is modestly immunogenic. - **TDM decision grid:** low trough plus high ADA — switch within class or out; low trough without ADA — intensify dose or shorten interval; high trough with active disease — the drug is present but ineffective, switch class. - **Switch types:** originator-to-biosimilar (cost-driven, common in India), biosimilar-to-biosimilar, class-to-class (anti-TNF failure in rheumatoid arthritis to rituximab or a JAK inhibitor) — each with different evidence bases. - **Biosimilar rules:** a biosimilar is not a copy — it matches the originator in structure and clinical performance within defined limits; approval allows extrapolation to indications tested indirectly, and CDSCO's 2016 biosimilar guidelines govern the Indian pathway. - **Indian anchors:** India has one of the largest biosimilar portfolios in the world — Indian trastuzumab, rituximab, etanercept and adalimumab biosimilars are in routine use, cutting costs dramatically; their availability is what makes oncology and rheumatology biologics viable outside corporate hospitals. - **Practice caution:** switching a well-controlled patient remains a considered decision — most guidance recommends against automatic non-medical switching at the individual level, while permitting tender-driven switches at programme level with monitoring. ## How a loss-of-response workup unfolds A 32-year-old with Crohn disease on infliximab 5 mg/kg eight-weekly who returns at month 14 with recurrent diarrhoea and a rising CRP. Before changing anything, measure: trough infliximab just before the next dose, ADA titres, CRP, albumin and faecal calprotectin. The trough is undetectable with high-titre antibodies — the drug is being cleared, not underdosed. The correct move is a switch, and because antibodies to the chimeric infliximab partly cross-react with the humanised pathway, many units go straight to a different mechanism (vedolizumab or a JAK inhibitor era option). Had the trough been therapeutic with active disease, switching class is again the answer — but for the opposite reason. Contrast the same patient who never skipped doses and takes methotrexate 15 mg weekly — ADA risk lowered from the start, the whole reason the combination is prescribed in inflammatory bowel disease and rheumatoid arthritis alike. ## How the exam frames it The PG pattern is the grid, not the drug: "a patient on adalimumab with low trough and high anti-drug antibodies — next step" expects switching (or dose intensification only if antibodies are absent), and "which co-medication reduces immunogenicity" expects methotrexate or azathioprine. A second layer asks what a biosimilar is and is not — highly similar, not identical; clinically equivalent in tested end points; extrapolation allowed — with CDSCO's 2016 biosimilar guidelines as the quotable anchor. Viva examiners push one step further: "can a pharmacist substitute a biosimilar?" — in India, biologic substitution is not automatic the way generic small molecules are, because biosimilars are not declared interchangeable without specific data; prescribing is by brand name in practice. The Indian economics completes the answer: biosimilar adalimumab at Indian prices is what keeps programme-level switching debates alive in public hospitals. ## Frequently asked questions ### What are anti-drug antibodies? Host antibodies induced by a biologic that neutralise it or accelerate its clearance, causing loss of response and infusion reactions — the core mechanism of secondary biologic failure. ### How does therapeutic drug monitoring guide switching? A low drug trough with high antibodies indicates immunogenic clearance (switch drug), a low trough without antibodies suggests underdosing (intensify), and a normal trough with active disease means pharmacological failure (switch class). ### Why is methotrexate co-prescribed with infliximab? Concomitant immunomodulation reduces anti-drug antibody formation, raises trough levels and improves durability of response in rheumatoid arthritis and Crohn disease. ### Is a biosimilar identical to the originator biologic? No — it is highly similar and clinically equivalent within regulatory limits; minor structural differences exist, and approval relies on comparability exercises plus extrapolation across indications, under CDSCO's 2016 biosimilar guidelines in India. ### When is switching out of the anti-TNF class indicated? When disease remains active despite adequate drug levels, or when class-limiting events occur (lupus-like syndrome, demyelination, recurrent serious infection, new heart failure), rather than for immunogenicity alone, which can be solved within class.